Editas presents pre-clinical data in Sickle Cell Disease, Beta-Thalassemia
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Editas announces data supporting novel approach for Sickle Cell,Beta-Thalassemia
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Vertex to study experimental gene-editing therapy as treatment for sickle cell, beta-thalassemia
Vertex Pharmaceuticals Inc. said Tuesday it plans to pay $1.1 billion to Crispr Therapeutics AG as part of a deal to test an experimental gene-editing therapy for sickle cell disease and transfusion-dependent beta-tha.....»»
Global Blood Therapeutics and Syros Pharmaceuticals partner for sickle cell therapies
Global Blood Therapeutics Inc. and Syros Pharmaceuticals Inc. announced a partnership to develop and commercialize therapies for sickle cell disease and beta thalassemia. Sickle cell .....»»
Novartis Presents Positive Data on Sickle Cell Disease Drug
Novartis (NVS) announces.....»»
CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study
CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study. .....»»
Agios" beta thal, sickle cell data should be positive, says Piper Sandler
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Vertex/CRISPR"s Sickle Disease Candidate Put on Hold by FDA
FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease. Vertex Pharmaceuticals Incorporated VRTX and partner CRISPR The.....»»
Crispr Therapeutics: What The FDA Clinical Hold On CTX-001 For Sickle Cell Disease Entails
Crispr Therapeutics: What The FDA Clinical Hold On CTX-001 For Sickle Cell Disease Entails.....»»
Global Blood Therapeutics Shares Plunge After Sickle Cell Candidate Shows Reduced Effect
Global Blood Therapeutics Inc (NASDAQ: GBT) shares were sliding Friday after the release of updated data for the company's sickle cell disease candidate that will be present read more.....»»
Global Blood Therapeutics reports positive data in trial of sickle cell disease treatment
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»
Global Blood Therapeutics shares drop after late-stage data for sickle cell disease treatment
Global Blood Therapeutics Inc. shares dropped as much as 12% in premarket trade on Wednesday after the company reported results for a late-stage trial of sickle cell disease therapy, and said that it met with the U.S. Food and Drug Ad.....»»
Global Blood Therapeutics Meets Primary Endpoints In Sickle Cell Study, Seeks Accelerated FDA Approval
Global Blood Therapeutics Inc (NASDAQ: GBT) shares were trading down off the open Wednesday after the company released data from its sickle cell disease candidate. read more.....»»
Axcella Health presents AXA1665-002 clinical study data at DDW
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Adagene presents clinical data from NEObody program
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
uniQure presents clinical data from phase III HOPE-B gene therapy trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Flexion presents preliminary FX201 clinical data at ASGCT meeting
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Intellia Therapeutics presents new data on expanded cell engineering
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Leap Therapeutics presents clinical data from Phase 2 trial of DKN-01
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Immatics Stock Trading Higher As Cell Therapy Program Shows Anti-Tumor Activities In Pretreated Cancer Patients
Immatics NV (NASDAQ: IMTX) has announced a clinical data update from the dose-escalation cohorts of the ongoing Phase 1 trial evaluating its ACTengine product candidates IMA201, IMA202, and IMA read more.....»»
Lilly"s stock is down after sharing additional clinical data about its Alzheimer"s disease drug candidate
ShaShares of Eli Lilly & Co. were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experi.....»»